Semax and Selank: normal, N-Acetyl, Amidate

Community discussion forums for cognitive and anxiolytic peptides regularly surface the same question: what is the practical difference between plain Selank or Semax and the N-Acetyl or N-Acetyl Amidate (NAA) versions of those peptides? The short answer is that all three variant names refer to chemical modifications at the ends of the peptide chain that change how quickly the body degrades the molecule. The modifications do not alter the core amino-acid sequence or the primary pharmacological targets. What they change is the peptide's stability against the enzymes that break peptides down.

The base molecules

Selank is a heptapeptide (seven amino acids) with the sequence Thr-Lys-Pro-Arg-Pro-Gly-Pro, synthesised as an analogue of the human immunomodulatory peptide tuftsin^[1]. It is registered in Russia as an anxiolytic and was developed at the Institute of Molecular Genetics of the Russian Academy of Sciences. Semax is a separate heptapeptide, sequence Met-Glu-His-Phe-Pro-Gly-Pro, built from a fragment of adrenocorticotropic hormone (ACTH 4-7) with a Pro-Gly-Pro stabilising tail added at the C-terminus^[2]. Both are registered prescription medicines in Russia, and neither has a marketing authorisation in the EU, UK, or US. The modifications described below are circulated in the research-peptide grey market; they are not part of any licensed formulation.

What N-Acetyl means

N-Acetyl refers to the attachment of an acetyl group (CH3CO-) to the free amine at the N-terminus, which is the start of the peptide chain. The N-terminus is one of the two main sites where proteolytic enzymes, particularly exopeptidases, begin chewing a peptide apart. Blocking it with an acetyl group sterically obstructs that enzymatic attack. John and colleagues (2008) demonstrated this principle directly in GLP-1 chemistry: an N-terminally acetylated GLP-1 variant was not degraded by the enzyme DPP-IV over at least two hours, whereas the unblocked peptide was rapidly cleaved at the same position^[3]. Critically, the acetylated variant retained its biological activity in that experiment, producing comparable insulin-releasing effects, which suggests the modification preserved receptor engagement while extending stability.

Applied to Selank and Semax, N-Acetyl modification means the compound spends more time in circulation before being cleared, rather than arriving at the intended receptor site in a degraded form. This is not the same as increasing potency at the receptor. The modification targets the pharmacokinetic half-life, not the pharmacodynamic effect size.

What Amidate means

Amidate (or amide) refers to a modification at the C-terminus, the other end of the chain. Normally a peptide ends in a free carboxyl group (-COOH). C-terminal amidation replaces that with an amide group (-CONH2). This blocks exopeptidase access from the tail end of the chain in the same way N-acetylation blocks it from the head. Brinckerhoff and colleagues (1999) measured the effect of terminal capping on peptide stability in human plasma: the unmodified form had a calculated half-life of just 22 seconds, while C-terminal amidation and N-terminal acetylation each extended survival in plasma significantly^[4]. The study confirmed that the modified peptides retained their biological function after modification.

C-terminal amidation also occurs naturally: more than 70 bioactive peptides in human physiology carry a native C-terminal amide, and the modification is often required for full biological activity in endogenous peptides. For synthetic analogues like Selank and Semax, amidation is added artificially during chemical synthesis.

Does the combined NA-Amidate form give a longer half-life?

The logic in community discussions is broadly correct: if N-terminal acetylation protects one end and C-terminal amidation protects the other, a doubly-capped peptide should survive longer than a singly-capped or bare peptide. That is what the terminal-modification literature supports in principle. However, no published study has measured the half-life of N-Acetyl Selank Amidate or N-Acetyl Semax Amidate specifically, in either rat or human plasma. The degradation timeline for the parent compounds in vivo is also not precisely characterised: the Dolotov study on Semax noted a half-life exceeding one hour in rat brain membrane preparations, but acknowledged the dominant degradative pathway runs through dipeptidylaminopeptidases that sequentially clip the molecule from the N-terminus^[2].

That mechanistic detail matters: if the main enzyme attacks from the N-terminus, N-terminal acetylation alone may confer most of the stability benefit, and the C-terminal amide may add comparatively less. The reverse could hold if C-terminal exopeptidases are the rate-limiting step. Without direct assay data on the modified forms, the relative contribution of each modification to total stability in the brain or bloodstream cannot be stated with precision.

What the modifications do not change

The core amino-acid sequence is identical across all three variants. Selank's anxiolytic mechanism, which the Vyunova (2018) review links to positive allosteric modulation of GABA receptors and to serotonin metabolism^[1], operates through the same structural motif in all three forms. The modifications sit at the termini, not within the receptor-binding portion of the sequence. There is no published evidence that N-Acetyl or Amidate Selank or Semax has a different receptor-level mechanism than the base compound, or that it affects a receptor the base compound does not.

Regulatory and safety context

Neither Selank nor Semax, in any form, holds a marketing authorisation outside Russia. The N-Acetyl and Amidate versions are not registered medicines anywhere. They are sold exclusively through the research-peptide grey market, which carries the legal and quality-assurance considerations that apply across that category. See the grey-market risk overview for Semax for the sourcing and legal context.

No human clinical trial has compared the three forms head-to-head, and there is no regulatory-grade safety dataset for N-Acetyl or Amidate variants of either peptide. The stability literature cited above comes from studies on structurally unrelated peptides, applied here as a general principle of peptide biochemistry rather than as direct evidence for Selank or Semax variants specifically. Always consult a healthcare provider before using any peptide, in any form.